The 1 June 2011 saw Pfizer file suit against Watson Pharmaceuticals Inc. in the United States District Court for the Southern District of New York in an attempt to prevent Watson commercializing its generic Viagra drug. This legal action could well be the first of many for Pfizer as its patents on Viagra expire between 2011-2013.
It is expected that generic drug manufacturers will make legal moves to end the Viagra patent before its deadline is up. Companies could either sue Pfizer claiming its patent is invalid or file with the Food and Drug Administration (FDA) to launch generics ahead of the deadline. Watson Pharmaceuticals have done the latter, seeking approval to market Sildenefil Citrate Tablets, a generic version of Pfizer’s Viagra.
It is understandable why generic manufacturers may attempt to knock even a few months off the patent. Viagra had a total U.S. sales of just over $1 billion for the twelve months ending April 2011. Even one month’s sales are worth $83 million. Equally so, it is understandable why Pfizer will be willing spend millions of dollars in legal fees to protect the patent.
In the long run, the expiration of Pfizer’s monopoly on Viagra will be good news for consumers, as it will result in competition between Pfizer’s Viagra and new generic versions, driving down the price of erectile dysfunction medication.
It is expected that generic drug manufacturers will make legal moves to end the Viagra patent before its deadline is up. Companies could either sue Pfizer claiming its patent is invalid or file with the Food and Drug Administration (FDA) to launch generics ahead of the deadline. Watson Pharmaceuticals have done the latter, seeking approval to market Sildenefil Citrate Tablets, a generic version of Pfizer’s Viagra.
It is understandable why generic manufacturers may attempt to knock even a few months off the patent. Viagra had a total U.S. sales of just over $1 billion for the twelve months ending April 2011. Even one month’s sales are worth $83 million. Equally so, it is understandable why Pfizer will be willing spend millions of dollars in legal fees to protect the patent.
In the long run, the expiration of Pfizer’s monopoly on Viagra will be good news for consumers, as it will result in competition between Pfizer’s Viagra and new generic versions, driving down the price of erectile dysfunction medication.
